Loading company
Ultragenyx Pharmaceutical Inc.
RARE · Nasdaq · ·
Next earnings: November 3, 2026
$15.32+6.3%Sep 29 close
- 1M
- -40.2%
- 6M
- -20.6%
- 1Y
- -49.1%
- 5Y
- -82.7%
Trailing twelve months where a flow is involved, latest reported balance where it is not.
Product is 55% of revenue.
Year to Dec 31, 2025 · $673M
Year to Dec 31, 2025 · $673M
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$717.21MQ2 2026+7.0%
Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.
-$495.17MQ2 2026+6.1%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.
-$585.97MQ2 2026+3.8%-81.7% of revenue
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
-81.7%Q2 2026+10.1%
How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.
-$489MQ2 2026+2.8%
Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.
-$5.83Q2 2026+4.4%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
100.53MQ2 2026+0.9%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
$0.00Q2 2014-100.0%
Cash handed to shareholders. A flat line at zero means the company pays none. Each quarter on its own, so seasonal highs and lows are visible.
Everything above comes from Ultragenyx Pharmaceutical Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Not reported by this filer: Gross Profit, Interest Expense, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Depreciation, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
RARE · Nasdaq · ·
Next earnings: November 3, 2026
$15.32+6.3%Sep 29 close